The field of HIV vaccine and prevention research continues to evolve as new insights are gained through animal studies and clinical trials. The Vaccine Discovery Group (VDG) aims to support this CHAVI-ID by providing insight and guidance to adjust research aims based on new findings during the life of the Center. This VDG will involve leadership from the clinical HIV vaccine field, along with key researchers with biotech, pharmaceutical and academic experience. Specifically, the VDG will provide guidance on vaccine development and administration based on personal insights and experiences in the field, and will provide data on how best to blend new outside knowledge into the research focus and aims of the CHAVI-ID, thereby ensuring the work of the Center remains at the forefront of addressing critical questions in the HIV vaccine research field. This will be accomplished by the following Specific Aims: 1. To share basic, practical knowledge about vaccine development and formulate creative strategies to advance ideas to products. 2. To provide sustained guidance to enable promising HlV-1 vaccine candidates to move forward into clinical evaluation.

Public Health Relevance

This Discovery Group supports the CHAVI-ID by providing direct linkages with the leaders and advisors in the clinical vaccine networks to more efficiently move products into phase 1 testing. This is critical for supporting the immunogen discovery activities of the Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI100663-03
Application #
8681352
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Pauthner, Matthias; Havenar-Daughton, Colin; Sok, Devin et al. (2017) Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity 46:1073-1088.e6
Mayer, Christian T; Gazumyan, Anna; Kara, Ervin E et al. (2017) The microanatomic segregation of selection by apoptosis in the germinal center. Science 358:
Richard, Jonathan; Prévost, Jérémie; von Bredow, Benjamin et al. (2017) BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. J Virol 91:
Andrabi, Raiees; Su, Ching-Yao; Liang, Chi-Hui et al. (2017) Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. Immunity 47:1004
Sok, Devin; Le, Khoa M; Vadnais, Melissa et al. (2017) Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 548:108-111
Polonskaya, Zinaida; Deng, Shenglou; Sarkar, Anita et al. (2017) T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest 127:1491-1504
Zeltina, Antra; Krumm, Stefanie A; Sahin, Mehmet et al. (2017) Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization. Proc Natl Acad Sci U S A 114:7031-7036
Baxter, Amy E; Niessl, Julia; Fromentin, Rémi et al. (2017) Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nat Protoc 12:2029-2049
Guenaga, Javier; Garces, Fernando; de Val, Natalia et al. (2017) Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein. Immunity 46:792-803.e3
Bale, Shridhar; Goebrecht, Geraldine; Stano, Armando et al. (2017) Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses. J Virol 91:

Showing the most recent 10 out of 276 publications